Illustration of doctor and patient

Cutting edge infectious disease molecular diagnostics to improve patient care.

Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels to address the global threat of antimicrobial resistance (AMR).

We provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs).

Together we improve patient care and fight AMR through cutting edge molecular microbiology.

Explore

Together we improve patient care and fight AMR through cutting edge molecular microbiology.

Press Releases

  • 3.25.24
    OpGen Announces Acquisition of Preferred Stock by David Lazar  MORE
  • 11.14.23
    OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update  MORE
  • 10.12.23
    OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds  MORE

See all news

Earnings Events

    There are currently no upcoming events.

    See all events

    Corporate Videos

    • OpGen – Edison Open House: Global Healthcare 2022 – YouTube
    • OpGen – Edison Open House: Global Healthcare 2021 – YouTube
    • OpGen CEO Oliver Schacht Appears on Infection Control Today – YouTube
    • OpGen CEO Oliver Schacht Appears on EdisonTV to Discuss the Future of the Combined Company – YouTube

    Watch

    Contact Us

    For more information on our products and services:

    • This field is for validation purposes and should be left unchanged.